{"id":68501,"date":"2025-02-19T11:25:07","date_gmt":"2025-02-19T09:25:07","guid":{"rendered":"https:\/\/www.synevo.md\/?post_type=product&#038;p=68501"},"modified":"2025-02-19T11:25:09","modified_gmt":"2025-02-19T09:25:09","slug":"proteina-tau-fosforilata-fosfo-tau-in-lichid-cefalo-rahidian","status":"publish","type":"product","link":"https:\/\/old.synevo.md\/ru\/shop\/proteina-tau-fosforilata-fosfo-tau-in-lichid-cefalo-rahidian\/","title":{"rendered":"Proteina tau fosforilata (fosfo-tau) in lichid cefalo-rahidian"},"content":{"rendered":"<p><strong>Informa\u021bii generale Proteina tau\/fosfo-tau in lichid cefalo-rahidian<\/strong><\/p>\n<p>Dozarea <strong>proteinelor tau\/ fosfo-tau in lichidul cefalorahidian (LCR)<\/strong> este recomandat\u0103 \u00een diagnosticul diverselor tulburari de cogni\u021bie aflate la debut, care pot evolua lent sau accelerat c\u0103tre demen\u021ba Alzheimer; diagnosticul diferen\u021bial al demen\u021bei Alzheimer cu alte tipuri de demen\u021b\u0103.<\/p>\n<p>Agregarea formelor hiperfosforilate ale proteinelor axonale tau \u00een soma neuronal\u0103, form\u00e2nd aglomerari neurofibrilare, este o caracteristic\u0103 patologic\u0103 cheie a bolii Alzheimer (BA), de\u0219i incluziunile tau din neuroni sau celule gliale se intalnesc \u0219i \u00een unele demen\u021be neurodegenerative non-AD, de exemplu, paralizia supranucleara progresiva \u0219i unele forme de demen\u021b\u0103 frontotemporal\u0103. \u00cempreun\u0103 cu raportul A\u03b242 \/ A\u03b240, proteinele T-tau \u0219i P-tau au fost propuse ca biomarkeri pentru a defini boala Alzheimer \u0219i sunt considera\u021bi de diagnostic \u00een criteriile de cercetare.<\/p>\n<p>At\u00e2t concentra\u021biile CSF T-tau, c\u00e2t \u0219i P-tau reflect\u0103 fiziopatologia legat\u0103 de AD, dar nu reflect\u0103 patologia tau \u00een tau-patiile ce nu sunt BA. Astfel, proteinele T-tau \u0219i P-tau pot fi considerate biomarkeri predictivi ai degenerarii cerebrale de tip AD \u0219i form\u0103rii aglomerarilor fibrilare, dar nu biomarkeri direc\u021bi ai acestor procese; nu sunt biomarkeri ai tauopatiilor non-AD, pentru care sunt necesari biomarkeri \u00eembun\u0103t\u0103\u021bi\u021bi. Cu toate acestea, T-tau cre\u0219te \u0219i \u00een tulbur\u0103rile neurodegenerative rapide f\u0103r\u0103 patologie amiloid\u0103 sau tau : boala Creutzfeldt-Jakob- afec\u021biuni acute, cum ar fi accident vascular cerebral \u0219i traumatisme cerebrale-suger\u00e2nd ca aceasta poate reflecta leziuni neuronale cu aceeasi etiologie.<\/p>\n<p>Diagnosticul tulbur\u0103rilor demen\u021bei degenerative primare, cum ar fi boala Alzheimer 1, se face \u00een mare parte prin excluderea altor cauze ale demen\u021bei<sup>1<\/sup>. C\u0103utarea giomarkerilor de diagnostic care ar putea fi utiliza\u021bi pentru un diagnostic precoce al bolii Alzheimer (BA), a condus la sugestia c\u0103 concentra\u021biile de proteine tau \u00een lichidul cefalorahidian (LCR) au o valoare de diagnostic<sup>2,3<\/sup>.<\/p>\n<p>Tau este o protein\u0103 axonal\u0103 normal\u0103, care prin legarea la tubulina din microtubulii axonali promoveaz\u0103 asamblarea \u0219i stabilitatea acestora<sup>4<\/sup>. At\u00e2t proteina tau normal\u0103, c\u00e2t \u0219i cea hiperfosforilat\u0103 sunt dispersate \u00een LCR<sup>5<\/sup>, iar m\u0103surarea concentra\u021biei de proteinei tau din LCR este posibil\u0103 prin utilizarea tehnologiilor imunoenzimatice<sup>6<\/sup>.<\/p>\n<p>O cre\u0219tere a proteinei tau din LCR \u00een <a href=\"https:\/\/www.synevo.ro\/informatii-medicale\/boala-alzheimer-cauza-dementei\/\" data-wpel-link=\"internal\" rel=\"nofollow noopener\" target=\"_blank\">boala Alzheimer<\/a>, a fost constatat\u0103 de numeroase studii<sup>1,2,4,5-10<\/sup>, care reflect\u0103 probabil degenerescen\u021ba axonal\u0103<sup>7,10 <\/sup>sau, acumularea succesiv\u0103 de suprapuneri neurofibrilare, \u00een cazul BA<sup>10<\/sup>. Sensibilitatea proteinelor tau din LCR pentru boala Alzheimer, \u00een mai multe studii, a fost ridicat\u0103, adesea \u223c80-90%<sup>11<\/sup>. Specificitatea a fost relativ ridicat\u0103, deoarece majoritatea pacien\u021bilor cu alte demen\u021be, tulbur\u0103ri neurologice cronice (de exemplu, boala Parkinson) sau diagnostic psihiatric (de exemplu, pseudo-demen\u021b\u0103 depresiv\u0103) au valori fiziologice ale proteinei tau in LCR.<\/p>\n<h2><strong>\u00a0<\/strong><strong>Recomand\u0103ri pentru determinarea proteinei tau \u0219i fosfo-tau<\/strong><sup>12<\/sup><\/h2>\n<ul>\n<li>Evaluarea adul\u021bilor cu tulbur\u0103ri cognitive (boala Alzheimer)<\/li>\n<\/ul>\n<p>Aceste teste nu pot fi deocamdat\u0103 utilizate pentru a prezice dezvoltarea demen\u021bei sau a altor afec\u021biuni neurologice sau pentru\u00a0 monitorizarea r\u0103spunsul la tratament (\u00een evaluare clinic\u0103).<\/p>\n<h2><strong>Preg\u0103tire pacient<\/strong><\/h2>\n<p>Timp de 12 ore \u00eenainte de colectarea specimenelor, nu se recomand\u0103 ingestia multivitaminelor sau suplimentelor alimentare care con\u021bin biotin\u0103 (vitamina B7).<\/p>\n<p><strong>Specimen recoltat <\/strong>\u2013 lichid cefalorahidian<sup>12<\/sup><\/p>\n<p><strong>Recipient de recoltare <\/strong>\u2013 Proba de LCR trebuie recoltat\u0103 \u00een tub de polipropilen\u0103<sup>12.\u00a0<\/sup><\/p>\n<p><strong>Volum prob\u0103 <\/strong>\u2013 2 mL<sup>12<\/sup><\/p>\n<p><strong>Cauze de respingere a probei <\/strong><sup>12<\/sup><\/p>\n<ul>\n<li>Specimen hemolizat<\/li>\n<li>Specimen icteric<\/li>\n<\/ul>\n<p><strong>Stabilitate prob\u0103<\/strong> \u20132 luni la -20\u00b0C. \u00cenainte de congelare, proba ar trebui centrifugat\u0103 pentru a \u00eenl\u0103tura eventualele componente celulare.<\/p>\n<p><strong>Metod\u0103 <\/strong>\u2013 electrochiluminiscent\u0103<sup>12<\/sup><\/p>\n<h2><strong>Valori de referin\u021b\u0103 Proteina tau\/fosfo-tau in lichid cefalo-rahidian<\/strong><\/h2>\n<p>Total-Tau: \u2264 238 pg\/mL<\/p>\n<p>Fosfo-Tau: \u2264 21.7 pg\/mL<\/p>\n<p><strong>\u00a0<\/strong><strong>\u00a0<\/strong><\/p>\n<h2><strong>\u0411\u0438\u0431\u043b\u0438\u043e\u0433\u0440\u0430\u0444\u0438\u044f<\/strong><\/h2>\n<ol>\n<li>Magnus Sjo\u0308gren, Hugo Vanderstichele, Hans A\u030agren, Olof Zachrisson, Mikael Edsbagge, Carsten Wikkels\u00f8, Ingmar Skoog, Anders Wallin, Lars-Olof Wahlund, Jan Marcusson, Katarina Na\u0308gga, Niels Andreasen, Pia Davidsson, Eugeen Vanmechelen, Kaj Blennow, Tau and A\u03b242 in Cerebrospinal Fluid from Healthy Adults 21\u201393 Years of Age: Establishment of Reference Values, Clinical Chemistry, Volume 47, Issue 10, 1 October 2001, Pages 1776\u20131781, <a href=\"https:\/\/doi.org\/10.1093\/clinchem\/47.10.1776\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1093\/clinchem\/47.10.1776<\/a><\/li>\n<li>Barth\u00e9lemy, N. R., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Bu\u00e9e, L., Gabelle, A., Junot, C., Lehmann, S., &amp; Becher, F. (2016). Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. Journal of proteome research, 15(2), 667\u2013676. <a href=\"https:\/\/doi.org\/10.1021\/acs.jproteome.5b01001\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1021\/acs.jproteome.5b01001<\/a><\/li>\n<li>Ritchie, C., Smailagic, N., Noel-Storr, A. H., Ukoumunne, O., Ladds, E. C., &amp; Martin, S. (2017). CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI). The Cochrane database of systematic reviews, 3(3), CD010803. <a href=\"https:\/\/doi.org\/10.1002\/14651858.CD010803.pub2\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1002\/14651858.CD010803.pub2<\/a><\/li>\n<li>Mitchell A. J. (2009). CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer\u2019s disease: a meta-analysis of 51 studies. Journal of neurology, neurosurgery, and psychiatry, 80(9), 966\u2013975. <a href=\"https:\/\/doi.org\/10.1136\/jnnp.2008.167791\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1136\/jnnp.2008.167791<\/a><\/li>\n<li>Arai, H., Ishiguro, K., Ohno, H., Moriyama, M., Itoh, N., Okamura, N., Matsui, T., Morikawa, Y., Horikawa, E., Kohno, H., Sasaki, H., &amp; Imahori, K. (2000). CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Experimental neurology, 166(1), 201\u2013203. <a href=\"https:\/\/doi.org\/10.1006\/exnr.2000.7501\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1006\/exnr.2000.7501<\/a><\/li>\n<li>Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., &amp; Trojanowski, J. Q. (2010). Total and phosphorylated tau protein as biological markers of Alzheimer\u2019s disease. Experimental gerontology, 45(1), 30\u201340. <a href=\"https:\/\/doi.org\/10.1016\/j.exger.2009.10.010\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1016\/j.exger.2009.10.010<\/a><\/li>\n<li>Palmqvist, S., Tideman, P., Cullen, N. et al (2021). Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27, 1034\u20131042. <a href=\"https:\/\/doi.org\/10.1038\/s41591-021-01348-z\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1038\/s41591-021-01348-z<\/a><\/li>\n<li>Smoter, M., Bodnar, L., Grala, B., Stec, R., Zieniuk, K., Kozlowski, W., &amp; Szczylik, C. (2013). Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel\/platinum first-line chemotherapy. Journal of experimental &amp; clinical cancer research : CR, 32(1), 25. <a href=\"https:\/\/doi.org\/10.1186\/1756-9966-32-25\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1186\/1756-9966-32-25<\/a><\/li>\n<li>Satoh, K., Shirabe, S., Tsujino, A., Eguchi, H., Motomura, M., Honda, H., Tomita, I., Satoh, A., Tsujihata, M., Matsuo, H., Nakagawa, M., &amp; Eguchi, K. (2007). Total tau protein in cerebrospinal fluid and diffusion-weighted MRI as an early diagnostic marker for Creutzfeldt-Jakob disease. Dementia and geriatric cognitive disorders, 24(3), 207\u2013212. <a href=\"https:\/\/doi.org\/10.1159\/000107082\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1159\/000107082<\/a><\/li>\n<li>Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., van de Voorde, A., Martin, J. J., &amp; Cras, P. (1993). Detection of tau proteins in normal and Alzheimer\u2019s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. Journal of neurochemistry, 61(5), 1828\u20131834. <a href=\"https:\/\/doi.org\/10.1111\/j.1471-4159.1993.tb09823.x\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1111\/j.1471-4159.1993.tb09823.x<\/a><\/li>\n<li>Andreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., R\u00e4ih\u00e4, I., Sourander, L., Winblad, B., &amp; Blennow, K. (1998). Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer\u2019s disease: a community based follow up study. Journal of neurology, neurosurgery, and psychiatry, 64(3), 298\u2013305. <a href=\"https:\/\/doi.org\/10.1136\/jnnp.64.3.298\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/doi.org\/10.1136\/jnnp.64.3.298<\/a><\/li>\n<li>Mayo Clinic. Mayo Medical Laboratories. Test Catalog. [on-line]: <a href=\"https:\/\/www.mayocliniclabs.com\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/www.mayocliniclabs.com<\/a> [Accesat la data de 11.07.2021]<\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"<p>Informa\u021bii generale Proteina tau\/fosfo-tau in lichid cefalo-rahidian Dozarea proteinelor tau\/ fosfo-tau in lichidul cefalorahidian (LCR) este recomandat\u0103 \u00een diagnosticul diverselor tulburari de cogni\u021bie aflate la debut, care pot evolua lent sau accelerat c\u0103tre demen\u021ba Alzheimer; diagnosticul diferen\u021bial al demen\u021bei Alzheimer cu alte tipuri de demen\u021b\u0103. Agregarea formelor hiperfosforilate ale proteinelor axonale tau \u00een soma neuronal\u0103, &hellip; <a href=\"https:\/\/old.synevo.md\/ru\/shop\/proteina-tau-fosforilata-fosfo-tau-in-lichid-cefalo-rahidian\/\">Continued<\/a><\/p>","protected":false},"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[15],"product_tag":[],"class_list":{"0":"post-68501","1":"product","2":"type-product","3":"status-publish","5":"product_cat-uncategorized","7":"first","8":"instock","9":"shipping-taxable","10":"purchasable","11":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product\/68501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/comments?post=68501"}],"wp:attachment":[{"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/media?parent=68501"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product_brand?post=68501"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product_cat?post=68501"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product_tag?post=68501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}